22 February 2021
Visiongain has published a new report on Plasma Protein Therapeutics Market Report 2021-2031: Forecasts By Product (Immunoglobulin, Albumin, Coagulation Factor, C1-esterase inhibitors, and Others), By Application (Hemophilia, Primary Immunodeficiency Disorder (PID), Idiopathic Thrombocytopenic Purpura, Secondary Immunodeficiency, Hereditary Angioedema, and Other Indications), By Patient Demographics (Adults, Geriatric, Pediatric), By End User (Hospitals, Homecare, Specialty Clinics, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) PLUS Profiles of Leading Manufacturing Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios.
Global Plasma Protein Therapeutics market was valued at US$ xx Million in 2020 and is projected to reach at a market value of US$ xx Million by 2031. North America dominated the global Plasma Protein Therapeutics market and is projected to witness CAGR of XX% during the first half of the forecast period i.e. 2021 to 2031.
COVID-19 Impact on Plasma Protein Therapeutics Market
COVID-19 impact through different recovery models such as V-shaped, U-shaped, W-shaped, and L-shaped; has been taken into consideration while estimating and forecasting the Plasma Protein Therapeutics market. Different recovery scenarios are also included in the report for all the segments and regions/nation. The recovery scenarios based on which market has been forecasted and analysed herein the report are mentioned below:
Availability of Reimbursement in Developing Nations
Demand for plasma protein therapeutics is increasing very rapidly due to availability of reimbursement in developing nations. Reimbursement from governments and private insurance players has increase significantly increasing for plasma protein therapeutics due to increase in plasma protein therapeutics based treatment around the world and which is also increasing demand of plasma protein therapeutics around the world due to this reason the factor is working as a driver for the plasma protein therapeutics market.
Increasing Therapeutic Advancements in Plasma Protein Therapeutics
Increasing number of immune deficiencies, autoimmune disorders, neurological & bleeding disorders,
shocks and burns cases had led various leading manufactures to increase their research and development activities for plasma protein therapeutics. Research and development activities for new technological advanced plasma protein therapeutics are helping to increase adoption of novel therapeutic in plasma protein therapeutics. Currently, many of the manufacturers are planning to launch their product portfolios in plasma protein therapeutics which is expected to fulfil demand and to work as a driver for the market.
Growing Awareness Regarding Plasma Protein Therapeutics
Governments, international organisations and regulatory authorities in various developing nations are making huge efforts for increasing awareness for plasma protein therapeutics. Increasing focus on raising awareness for plasma protein therapeutics is expected to untapped the potential markets in the emerging nations by increasing the plasma protein therapeutics treatment rate and increasing public spending towards it. Due to this reason the factor is expected to create various opportunities for the plasma protein therapeutics market.
Top companies (Baxter International, Biotests, CSL Behring, and GRIFOLS, S.A) constitute more than XX% share of the global Plasma Protein Therapeutics market. Other companies profiled in the report include: Kedrion, Octapharma USA, Inc., Shire Plc., China Biologics., and Emergent BioSolutions, Takeda Pharmaceutical Company Ltd some of the key developments are listed below:
● In 2019, Plasma Protein Therapeutics Association (PPTA) celebrated the seventh annual International Plasma Awareness Week (IPAW). The major focus of this conference is to increase awareness about plasma therapy, and expand lifesaving plasma protein therapies understanding from its collection to usage. The conference has helped to increase awareness regarding plasma protein therapeutics which will help the market to grow in the forecasted period.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Global liposomal drug delivery devices market is projected to grow at a CAGR of 10.69% by 2032.
21 June 2022
The global nanotechnology in drug delivery market was valued at US$53.0 billion in 2021 and is projected to grow at a CAGR of 18.7% during the forecast period 2022-2032.
20 June 2022
The global respiratory drug delivery technologies market was valued at US$59.51 billion in 2022 and is projected to grow at a CAGR of 7.31% during the forecast period 2022-2032.
15 June 2022
The global artificial intelligence (AI) in drug discovery market was valued at US$791 million in 2021 and is projected to grow at a CAGR of 30.7% during the forecast period 2022-2032.